glp 1 agonists approved for weight loss GLP-1s Loss: What You Need to Know Study finds GLP-1 receptor agonists
Description
Diabetes Ther 12 , 879896 (2021)

The findings from a large, cardiovascular event-driven safety trial, which compares tirzepatide and dulaglutide among 12,500 participants in the SURPASS-CVOT trial, are expected to be published in the near future

B., Copelovitch, L

Artificial Intelligence (AI) is transforming the obesity GLP-1 market by enabling personalized treatment strategies through patient profiling, predictive analytics, and biomarker identification

The platforms real-time messaging with providers, transparent documentation, and monthly check-ins ensure patients feel heard and guided throughout their journey

Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al